Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (1320)	1/28/2000 1:25:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

TB: BIOM sold their Diagnostic division some time ago, to concentrate on their Therapeutic products. As you know the FDA had already approved the TRUQUANT diagnostic tests for breast cancer. Procyon Biopharma's diagnostic products may be at a stage that they could be "licensed" to some other company, bu their therapeutic products have not started human experimental phase as yet. When they do and complete successfully a Phase II. It will be some time and a lot more money required before they could consider starting a phase III trial. Good luck. Bernard